Honors & Awards

  • Young Investigator Award, ASCO (2014)
  • KL2 Fellowship, Spectrum (2014-2016)

Research & Scholarship

Current Research and Scholarly Interests

My primary research interest is in improving outcomes in acute myeloid leukemia (AML). From a clinical trial standpoint, I am interested in combining novel small molecule inhibitors with conventional chemotherapy. From a population-based standpoint, I am conducting a retrospective analysis of outcomes in AML patients at Stanford who have undergone hematopoietic cell transplantation, as well as a collaborative project with the Cancer Prevention Institute of California analyzing outcomes in AML patients with data from the Surveillance and Epidemiology End Results (SEER).


All Publications

  • Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis CANCER Percival, M. M., Tao, L., Medeiros, B. C., Clarke, C. A. 2015; 121 (12): 2004-2012


    Acute myeloid leukemia (AML) is treated with conventional induction chemotherapy shortly after diagnosis for the majority of patients aged ≤65 years. A recent report suggested a substantial decline in the early, or 1-month, mortality rate in patients treated on clinical trials over the past 2 decades. It is unknown whether a similar improvement has been observed in the general population.The authors examined the 1-month mortality rate in a large population-based series of 9380 patients with AML who were aged ≤65 years and were diagnosed and treated with chemotherapy between 1973 and 2010.A significant decline was observed in the 1-month mortality rate from 18.7% among patients diagnosed from 1973 through 1977 (95% confidence interval [95% CI], 16.4%-21.2%) to 5.8% for those diagnosed between 2008 and 2010 (95% CI, 4.5%-7.6%) (P <.001). The median overall survival improved significantly from 6 months (95% CI, 5 months-7 months) in 1973 to 1977 to 23 months (95% CI, 16 months-20 months) in 2008 to 2010 (P <.001). Although age and geographic variation were found to significantly influence the 1-month mortality for the period between 1973 and 1977, these differences in 1-month mortality were no longer significant among patients with AML who were treated more recently (2008-2010).Over the past 4 decades, early mortality has become uncommon in younger patients (aged ≤65 years) with newly diagnosed AML undergoing induction chemotherapy. It is encouraging that the improvements noted in 1-month mortality rate among a selective cohort of patients in clinical trials have also been observed in a population-based analysis. Cancer 2015. © 2015 American Cancer Society.

    View details for DOI 10.1002/cncr.29319

    View details for Web of Science ID 000355768300015

Stanford Medicine Resources: